What are the causes, evaluation, and management of jaundice in a patient with beta‑thalassemia?

Jaundice in Beta-Thalassemia: Causes, Evaluation, and Management

Jaundice in beta-thalassemia results primarily from chronic hemolysis causing unconjugated hyperbilirubinemia, but you must systematically rule out hepatic causes—particularly chronic viral hepatitis (HBV/HCV), iron overload-related liver disease, and biliary obstruction from pigment gallstones—as these directly impact mortality and require specific interventions.

Primary Causes of Jaundice

Hemolytic Component (Most Common)

• Chronic hemolysis from ineffective erythropoiesis produces unconjugated (indirect) hyperbilirubinemia
• Severity increases with:
  • Alpha-globin gene triplication (present in 15.4% of thalassemia intermedia patients), which can cause marked bilirubin elevation during intercurrent illness 1
  • Co-inherited Gilbert syndrome or Crigler-Najjar syndrome (rare but causes persistent severe jaundice) 2

Hepatic Causes (Critical for Mortality)

Chronic viral hepatitis is the most important treatable cause:

• HCV infection: 4.4-85.4% prevalence globally in transfusion-dependent patients 3
• HBV infection: 0.3-5.7% prevalence, higher in Asia 3
• Cirrhosis develops in 10-20% of thalassemia patients with chronic hepatitis, strongly associated with male sex, elevated ALT, positive HCV-RNA, and high liver iron concentration 3

Iron overload hepatopathy from chronic transfusions causes hepatocellular dysfunction and can precipitate diabetes and cardiac complications 4

Biliary Obstruction

• Pigment gallstones from chronic hemolysis can cause choledocholithiasis and acute cholangitis 5
• Requires urgent intervention when complicated by infection

Evaluation Algorithm

Step 1: Differentiate Unconjugated vs Conjugated Hyperbilirubinemia

• Fractionated bilirubin: Determines if predominantly indirect (hemolytic) or direct (hepatic/obstructive)
• Reticulocyte count, LDH, haptoglobin: Confirms ongoing hemolysis 6

Step 2: Screen for Viral Hepatitis (Mandatory)

• HBsAg and anti-HCV antibodies by enzyme immunoassay 3
• If anti-HCV positive: Obtain HCV-RNA by PCR to confirm active viremia (only ~50% of anti-HCV positive thalassemia patients have active infection) 3
• HCV genotyping if RNA-positive (genotype 1b most common; determines treatment duration) 3

Step 3: Assess Liver Disease Severity

• ALT/AST, albumin, INR: Evaluate hepatocellular function
• Noninvasive liver iron assessment: MRI preferred over liver biopsy due to sampling variability in cirrhotic patients 3
• Liver fibrosis assessment: Noninvasive methods (elastography) preferred; liver biopsy has limitations in thalassemia due to iron distribution variability 3

Step 4: Evaluate for Biliary Obstruction

• Ultrasound: First-line imaging for gallstones, bile duct dilation, splenomegaly 7
• If obstructive pattern: MRCP or ERCP for choledocholithiasis 5

Step 5: Consider Co-inherited Bilirubin Metabolism Disorders

• If persistent severe unconjugated hyperbilirubinemia despite stable hemolysis, consider UGT1A1 gene testing for Gilbert or Crigler-Najjar syndrome 2

Management Strategy

For Hemolytic Jaundice

• Optimize transfusion regimen: Maintain hemoglobin >9 g/dL to suppress ineffective erythropoiesis
• Intensify chelation therapy if iron overload present (reduces hepatic iron burden) 3
• Monitor for intercurrent illness in patients with alpha-triplication (can cause marked bilirubin spikes) 1

For Chronic Viral Hepatitis (Reduces Mortality)

HCV-positive patients with active viremia:

• Combination Peg-interferon plus ribavirin for chronic hepatitis or compensated cirrhosis 3
• Duration: 48 weeks for genotype 1/4; 24 weeks for genotype 2/3 3
• Stopping rule: Discontinue if HCV-RNA fails to decrease ≥2 log units at 12 weeks (genotype 1/4) 3
• Increase transfusions during antiviral therapy to maintain hemoglobin >9 g/dL 3
• Intensify chelation before starting if severe iron burden present 3

HBV-positive patients:

• Peg-interferon (48 weeks) or nucleoside/nucleotide analogs (NUCs) for finite or long-term treatment 3
• First-line NUCs: Tenofovir or entecavir (high barrier to resistance) for HBeAg-negative patients or those not achieving HBe seroconversion 3

For Biliary Obstruction

• ERCP with stone extraction followed by cholecystectomy for choledocholithiasis 5
• Urgent intervention if acute cholangitis (fever, RUQ pain, jaundice)

For Iron Overload Hepatopathy

• Aggressive chelation therapy with monitoring of liver iron by MRI
• Screen for endocrine complications (diabetes, hypogonadism) 4

Critical Pitfalls to Avoid

1. Do not assume all jaundice is hemolytic: Viral hepatitis screening is mandatory in all transfusion-dependent patients, as cirrhosis develops in 10-20% and is preventable with antiviral therapy 3

2. Do not rely on anti-HCV alone: 50% of anti-HCV positive patients have cleared infection; confirm with HCV-RNA before initiating treatment 3

3. Do not perform liver biopsy routinely: Use noninvasive methods (MRI for iron, elastography for fibrosis) as biopsy has poor accuracy in cirrhotic thalassemia patients 3

4. Do not overlook biliary obstruction: Pigment stones are common; ultrasound should be part of initial evaluation 5

5. Recognize alpha-triplication: These patients (15.4% of thalassemia intermedia) develop marked jaundice with intercurrent illness requiring closer monitoring 1